Table 2

Baseline characteristics of all patients in the external cohort

N=108
Age (years)73 (68, 78)
Gender, women20 (18.5)
Race, non-white29 (26.9)
Body mass index (kg/m2)26.1±3.2
Comorbid disease
 Smoking status ever76 (70.4)
 Diabetes mellitus23 (21.3)
 Hypertension42 (38.9)
 Cardiovascular disease44 (40.7)
 Severe OSA17 (15.7)
 Lung cancer4 (3.7)
Measures of IPF severity and management considerations
 FVC (%) predicted81.0±19.5
 FEV1/FVC (%)83.0 (79.0, 86.0)
 DLCO (%) predicted47.4±15.7
 DLCO not performed3 (2.8)
 6MWD (m)473 (430, 559)
 Surgical lung biopsy21 (19.4)
 Antifibrotic therapy*67 (62.0)
 Pirfenidone32 (29.6)
 Nintedanib50 (46.3)
 Exertional hypoxia45 (42.1)
 Prescribed oxygen36 (33.3)
 Observed desaturation†9 (8.3)
GAP stage‡
 143 (39.8)
 249 (45.4)
 316 (14.8)
  • Data presented as mean±SD, median (25th percentile, 75th percentile) or n (%).

  • Most patients in this cohort were classified by the GAP index as having stage I (39.8%) or stage II (45.4%) disease.

  • *Antifibrotic therapy for at least 6 months (some patients transitioned between therapies).

  • †Observed desaturation during 6 min walk test in the absence of a prior oxygen prescription.

  • ‡GAP stage as classified by the original GAP index proposed and validated by Ley et al.5

  • DLCO, diffusion capacity for carbon monoxide; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; GAP, gender-age-physiology; 6MWD, 6 min walk distance.